Skip to main content
Shanghai Hile Bio-Technology Co.,Ltd logo

Shanghai Hile Bio-Technology Co.,Ltd — Investor Relations & Filings

Ticker · 603718 ISIN · CNE1000022T4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2026-01-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603718

About Shanghai Hile Bio-Technology Co.,Ltd

http://www.hile-bio.com/

Shanghai Hile Bio-Technology Co., Ltd. specializes in the research, development, production, and distribution of veterinary biological products. The company focuses on providing comprehensive health solutions for the livestock and poultry sectors. Its core product portfolio includes a wide range of vaccines targeting major animal diseases, such as swine fever, porcine reproductive and respiratory syndrome (PRRS), foot-and-mouth disease, and various avian influenza strains. Utilizing advanced biotechnology and large-scale manufacturing processes, the company operates high-standard production facilities compliant with Good Manufacturing Practice (GMP) requirements. Hile Bio-Technology emphasizes innovation through its dedicated research and development centers, aiming to enhance animal disease prevention and control. The company serves large-scale farming enterprises and veterinary service providers, maintaining a significant presence in the animal health sector through its commitment to product quality and technical support.

Recent filings

Filing Released Lang Actions
海利生物关于全资子公司医疗器械生产许可证变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the change of a medical device production license for a wholly-owned subsidiary of the company. It includes details about the license number, validity period extension, and address change. There is no financial data, no mention of financial results, no regulatory certifications, or detailed reports. The document is an official announcement about a regulatory license change, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not a management or board change announcement. Given the nature of the content and the short length (824 characters), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2026-01-22 Chinese
海利生物关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Haili Biotechnology Co., Ltd. regarding the completion of industrial and commercial registration changes, including cancellation of the supervisory board, change of registered address, business scope, and amendments to the company charter. It also mentions the completion of repurchase and cancellation of restricted shares and changes in registered capital. The document is relatively short (1464 characters) and primarily serves as a formal notice of these corporate changes and registration updates. It does not contain detailed financial statements, management discussion, or comprehensive report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-01-19 Chinese
海利生物关于2023年限制性股票与股票期权激励计划部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement from Shanghai Haili Biotechnology Co., Ltd. regarding the completion of a partial repurchase and cancellation of restricted shares under the 2023 restricted stock and stock option incentive plan. It details board resolutions, regulatory compliance, share structure changes, and official registration updates. The document is relatively short (1350 characters) and focuses on the execution and completion of a share repurchase and cancellation event, including changes in share capital and related disclosures. This fits the category of a Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares. It is not an annual or interim report, nor a regulatory filing or announcement of a report publication. Therefore, the correct classification is POS with high confidence.
2026-01-12 Chinese
海利生物关于2023年限制性股票与股票期权激励计划部分限制性股票回购注销实施公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Shanghai Haili Biotechnology Co., Ltd. regarding the repurchase and cancellation of restricted shares under the 2023 restricted stock and stock option incentive plan. It details the reasons for the repurchase, the number of shares involved, the board resolutions, legal compliance, and the impact on share capital structure. The document is a formal disclosure about a share repurchase and cancellation event, not a financial report, earnings release, or management discussion. It fits the category of Transaction in Own Shares (POS), which covers company announcements about buying back or canceling its own shares. The document length is under 5,000 characters and contains detailed information about the share repurchase and cancellation, not just a brief notice or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2026-01-06 Chinese
陕西瑞盛生物科技有限公司拟股权收购事宜涉及的常州武进金铂利口腔门诊部有限公司股东全部权益资产评估报告
Regulatory Filings
2025-12-31 Chinese
陕西瑞盛生物科技有限公司拟股权收购事宜涉及的溧阳溧城金铂利口腔门诊部有限公司股东全部权益资产评估报告
Regulatory Filings
2025-12-31 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.